Therapeutic potential of boron-containing compounds

SJ Baker, CZ Ding, T Akama, YK Zhang… - Future medicinal …, 2009 - Taylor & Francis
Relative to carbon, hydrogen, nitrogen and oxygen, very little is currently known about boron
in therapeutics. In addition, there are very few boron-containing natural products identified to …

Boron Neutron Capture Therapy (BNCT) for Cutaneous Malignant Melanoma Using 10Bp-Boronophenylalanine (BPA) with Special Reference to the Radiobiological …

H Fukuda - Cells, 2021 - mdpi.com
BNCT is a radiotherapeutic method for cancer treatment that uses tumor-targeting 10B-
compounds. BNCT for cutaneous melanoma using BPA, a phenylalanine derivative, was …

Acute and subchronic toxicity analysis of surface modified paclitaxel attached hydroxyapatite and titanium dioxide nanoparticles

GD Venkatasubbu, S Ramasamy… - International journal …, 2015 - Taylor & Francis
Nanoparticles are widely used for targeted drug delivery applications. Surface modification
with appropriate polymer and ligands is carried out to target the drug to the affected area …

Susceptibility to hydrolysis of phenylboronic pinacol esters at physiological pH

C Achilli, A Ciana, M Fagnoni, C Balduini… - … European Journal of …, 2013 - Springer
Boronic acids and their esters are highly considered compounds for the design of new drugs
and drug delivery devices, particularly as boron-carriers suitable for neutron capture …

Boron nanoparticles in chemotherapy and radiotherapy: the synthesis, state-of-the-art, and prospects

SA Uspenskii, PA Khaptakhanova - Russian Chemical Bulletin, 2022 - Springer
Boron neutron capture therapy (BNCT) is a radiotherapy method for cancer treatment based
on the nuclear reaction of the stable 10B isotope with epithermal neutrons that produces …

Selective thermal neutron capture therapy of cancer cells using their specific metabolic activities—melanoma as prototype

Y Mishima - Cancer neutron capture therapy, 1996 - Springer
It was around 1972 when it occurred to me that the accentuated melanogenesis occurring
parallel and specific to the transformation of pigment cells to malignant melanoma could be …

Drugs for BNCT: BSH and BPA

WAG Sauerwein, PM Bet, A Wittig - Neutron Capture Therapy: Principles …, 2012 - Springer
This chapter is based on a shortened version of the investigators brochures from the EORTC
clinical trials 11001 and 11011 concerning the boron compounds sodium borocaptate (BSH) …

4-Borono-2-[18F] fluoro-D, L-phenylalanine: a possible tracer for melanoma diagnosis with PET

K Ishiwata, T Ido, C Honda, M Kawamura… - International journal of …, 1992 - Elsevier
Abstract The potential of 4-borono-2-[18 F] fluoro-d, l-phenylalanine ([18 F] FBPA), a
fluorinated derivative of a target compound for boron neutron capture therapy, for melanoma …

Selective thermal neutron capture therapy and diagnosis of malignant melanoma: from basic studies to first clinical treatment

Y Mishima, M Ichihashi, S Hatta, C Honda… - Clinical Aspects of …, 1989 - Springer
As melanoma genesis occurs in pigment cells, accentuated melanogenesis concurrently
occurs in principlel. Thus, harnessing this accentuation of melanogenesis, we developed a …

Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent

KZ Matalka, MQ Bailey, RF Barth, AE Staubus… - Cancer research, 1993 - AACR
A rat brain tumor model has been developed utilizing nude rats and the human melanoma
cell line MRA 27. For pharmacokinetic and tissue distribution studies, 2 105 MRA 27 cells …